Healthcare / BiotechnologyShenzhen
$9.80
-0.12 (-1.21%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $118.1M · quality 45.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
28/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$6.5B
P/E
N/A
•EV/EBITDA
N/A
•ROE
386.4%
↑Gross Margin
27.3%
↓Debt/Equity
-4.07
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-10.0%
FCF CAGR
—
FCF margin
7.4%
FCF / Net income
-0.08x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.60B · net income $-1.39B · FCF $118.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.60B | $1.60B | $1.86B | $2.30B | $2.19B |
| Net Income | $-1.39B | $-1.39B | $-858.6M | $-389.0M | $-530.1M |
| EBITDA | $-858.3M | $-858.3M | $-382.8M | $85.4M | $-59.3M |
| EPS | -2.11 | -2.11 | -1.30 | -0.59 | -0.80 |
| Gross Margin | 27.3% | 27.3% | 24.4% | 34.3% | 24.9% |
| Operating Margin | -4.8% | -4.8% | -7.7% | 6.0% | -6.6% |
| Net Margin | -87.3% | -87.3% | -46.2% | -16.9% | -24.2% |
| Balance Sheet | |||||
| Debt/Equity | -4.07 | -4.07 | 2.13 | 1.26 | 1.07 |
| Current Ratio | 0.26 | 0.26 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $118.1M | $118.1M | $-17.1M | $207.4M | $-139.9M |
| Returns | |||||
| ROE | 386.4% | 386.4% | -81.4% | -20.2% | -23.0% |
| Valuation | |||||
| EV/EBITDA | — | — | — | 66.26 | — |
| P/B | — | — | 6.17 | 1.75 | 1.71 |
| Growth & Yield | |||||
| Revenue Growth | -14.2% | -14.2% | -19.2% | 5.1% | — |
| EPS Growth | -62.3% | -62.3% | -120.3% | 26.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+11.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.30 → -2.11
Residual
+11.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.